BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 22439831)

  • 1. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
    Svoboda M; Sana J; Redova M; Navratil J; Palacova M; Fabian P; Slaby O; Vyzula R
    Diagn Pathol; 2012 Mar; 7():31. PubMed ID: 22439831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
    Zeng Z; Chen X; Zhu D; Luo Z; Yang M
    Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.
    Cascione L; Gasparini P; Lovat F; Carasi S; Pulvirenti A; Ferro A; Alder H; He G; Vecchione A; Croce CM; Shapiro CL; Huebner K
    PLoS One; 2013; 8(2):e55910. PubMed ID: 23405235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
    Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers.
    Jonsdottir K; Janssen SR; Da Rosa FC; Gudlaugsson E; Skaland I; Baak JP; Janssen EA
    PLoS One; 2012; 7(11):e48692. PubMed ID: 23144930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum haptoglobin is associated with clinical outcome in triple-negative breast cancer patients.
    Tabassum U; Reddy O; Mukherjee G
    Asian Pac J Cancer Prev; 2012; 13(9):4541-4. PubMed ID: 23167376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients.
    Liu L; Liu Z; Qu S; Zheng Z; Liu Y; Xie X; Song F
    Diagn Pathol; 2013 May; 8():71. PubMed ID: 23635316
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
    Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
    [No Abstract]   [Full Text] [Related]  

  • 9. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer.
    Wu M; Wei W; Xiao X; Guo J; Xie X; Li L; Kong Y; Lv N; Jia W; Zhang Y; Xie X
    Med Oncol; 2012 Dec; 29(5):3240-9. PubMed ID: 22661383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential of miR-940 as a diagnostic and prognostic biomarker in breast cancer patients.
    Liu W; Xu Y; Guan H; Meng H
    Cancer Biomark; 2018; 22(3):487-493. PubMed ID: 29843213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vimentin as a poor prognostic factor for triple-negative breast cancer.
    Yamashita N; Tokunaga E; Kitao H; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Aishima S; Morita M; Maehara Y
    J Cancer Res Clin Oncol; 2013 May; 139(5):739-46. PubMed ID: 23354842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer.
    Kim SK; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2014; 7(6):3224-34. PubMed ID: 25031743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.
    Nassar FJ; El Sabban M; Zgheib NK; Tfayli A; Boulos F; Jabbour M; El Saghir NS; Talhouk R; Bazarbachi A; Calin GA; Nasr R
    PLoS One; 2014; 9(9):e107566. PubMed ID: 25232827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer.
    Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY
    Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
    Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
    J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 10-year follow-up of triple-negative breast cancer patients in Taiwan.
    Lin C; Chien SY; Kuo SJ; Chen LS; Chen ST; Lai HW; Chang TW; Chen DR
    Jpn J Clin Oncol; 2012 Mar; 42(3):161-7. PubMed ID: 22287721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer.
    Wu K; Huang S; Zhu M; Lu Y; Chen J; Wang Y; Lin Q; Shen W; Zhang S; Zhu J; Shi YE; Weng Z
    Med Oncol; 2013; 30(3):612. PubMed ID: 23696021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.